CD28 and neoplasm: Successful in vivo studies using 4-1BB/CD28 third generation CARs include an ICAM-1 CAR for a mouse model of thyroid cancer (40), a GPC3 CAR in a patient derived xenograft of model of HCC (32), and a VEGFR2 CAR against multiple tumor types in vivo (161).